country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-127055

Copy Link Print Information

Tiadenol

Tiadenol is an orally effective lipid-lowering compound and peroxisome proliferator. Tiadenol promotes peroxisome-associated fatty acid metabolism, and its induction of the activities of enzymes such as palmitoyl-CoA hydrolase, carnitine acetyl-transferase and catalase is mainly associated with de novo protein synthesis. The triglyceride-lowering effect of Tiadenol is not accompanied by increased activities of lipoprotein lipase (LPL) and hepatic lipase (HL), and it reduces VLDL Apo E. Tiadenol can be used in studies related to lipid metabolism, peroxisome proliferation and hyperlipoproteinemia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 6964-20-1
分子式: C₁₄H₃₀O₂S₂
分子量:294.52

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (269 KB)

Tiadenol 構造式

CAS 番号: 6964-20-1

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Apolipoprotein アイソフォーム固有の製品をすべて表示 :

体外実験

Lipid Metabolism

Tiadenol (2-20 μM; 4 days-6 weeks) induces dose- and time-dependent increases in palmitoyl-CoA hydrolase, catalase, cyanide-insensitive palmitoyl-CoA oxidation, and carnitine acetyl-transferase activities in non-transformed C3H/10T1/2 C18 and transformed C3H/10T1/2 MCA16 mouse embryo fibroblasts, with maximal induction at 2-5 μM and effects dependent on de novo protein synthesis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Lipid Metabolism

Tiadenol (0.27 g/day/kg body weight; p.o.; daily; 10 days) induces hepatomegaly, increases hepatic free CoASH, long-chain acyl-CoA, and activities of multiple lipid-metabolizing enzymes (including a 10-20-fold increase in peroxisomal palmitoyl-CoA oxidation), and causes subcellular redistribution of key hepatic enzymes in male Wistar rats^[3].
Tiadenol (500 mg/kg; p.o.; daily; 7 days) increases liver weight and catalase activity, decreases plasma cholesterol and total lipids, reduces biliary cholesterol concentration and output, increases bile flow and the cholesterol solubility ratio, and elevates the bile salt-independent fraction of bile secretion in normolipidemic rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (male, 250-270 g)^[3]
Dosage:

0.27 g/day/kg body weight
Administration:

p.o.; daily; 10 days
Result:

Increased liver weight, hepatic protein, free CoASH, and long-chain acyl-CoA.
Increased palmitoyl-CoA hydrolase, peroxisomal palmitoyl-CoA oxidation, and total catalase activity.
Induced marked redistribution of several hepatic peroxisomal/lipid-metabolizing enzyme activities among subcellular fractions.

Animal Model:

Wistar (male)^[1]
Dosage:

500 mg/kg
Administration:

p.o.; daily; 7 days
Result:

Decreased plasma cholesterol and total plasma lipids.
Increased liver weight and liver catalase.
Increased basal bile flow.
Decreased biliary bile salt, phospholipid, and cholesterol concentrations and cholesterol output.

Related Protocols :

Cell Viability Determination by MTT Colorimetric Assay

化学情報

CAS 番号 6964-20-1
分子量 294.52
分子式 C₁₄H₃₀O₂S₂
SMILES

OCCSCCCCCCCCCCSCCO
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (269 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Rozé C, et al. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat. European journal of pharmacology. 1977 May 01;43(1):57-64. [Content Brief]

[2]. Franceschini G, et al. Pharmacological studies on tiadenol in type IV patients: Evidence for a mechanism of action different from other lipid-lowering drugs. Atherosclerosis. 1981;40:245-255. [Content Brief]

[3]. Bakke OM, et al. Lipid-metabolizing enzymes, CoASH and long-chain acyl-CoA in rat liver after treatment with tiadenol, nicotinic acid and niadenate. Biochem Pharmacol. 1982;31(23):3930-3933.

[4]. Berge RK, et al. Tiadenol-mediated induction of peroxisomal enzymes in cultured C3H/10T1/2 CL8 cells and in chemically transformed C3H/10T1/2 MCA16 cells. Int J Cancer. 1985;36:489-494. [Content Brief]

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ